Tesamorelin Dosage Guide: Protocols, Calculator & Safety
Everything you need to know about Tesamorelin dosing — protocols, safety, and where to buy.
Dose Range
1,000–2,000 mcg (1–2 mg) daily
Frequency
Once daily subcutaneous injection
Cycle Length
12–26 weeks in clinical trials; ongoing use common
Half-Life
30-50 minutes (plasma)
Administration Routes
Quick Reconstitution Calculator
Calculate syringe units instantly
Syringe Draw
10.0 units
2500 mcg/ml · 0.100 ml draw
Dosing Protocols
Goal: match the FDA-approved protocol used in the pivotal HIV lipodystrophy trials.
Standard tesamorelin protocol — weeks 1-12
- Dose: 2 mg subcutaneous, once daily
- Timing: Pre-bed, fasted (≥2 hours post-meal). The pre-bed injection amplifies the nocturnal GH burst, which is the body's largest physiologic pulse and where tesamorelin's mechanism is most efficient
- Site: Abdominal subcutaneous fat, at least 2 inches from the navel; rotate L/R each day
- Needle: 29-31G × 1/2" insulin syringe
- Reconstitution: 2 mg vial + 2.1 mL 0.9% sterile sodium chloride (per package insert) OR 1 mL bacteriostatic water for off-label use; reconstituted solution is single-use per FDA label but typically stable for 5-7 days refrigerated in practice
- Storage: Refrigerate unreconstituted vial; reconstituted solution: use immediately (per label) or within 5 days refrigerated (off-label)
What to expect in weeks 1-12
- Weeks 1-2: Injection site mild redness/itch; possible mild head-heaviness post-injection; sleep may deepen
- Weeks 2-4: Peripheral edema (mild) may appear; joint stiffness onset; IGF-1 rising
- Weeks 4-8: IGF-1 typically reaches steady state; VAT reduction beginning but not yet visually apparent
- Weeks 8-12: Waist circumference reduction becoming measurable (~1-2 cm typical); subjective improvement in sleep quality, recovery, body composition
- Full protocol (26 weeks, per Phase 3 trial): ~15-18% VAT reduction from baseline; DEXA or CT can quantify
Required monitoring
- Baseline: IGF-1, fasting glucose, HbA1c, CMP, lipid panel, PSA (men >40), thyroid panel
- Week 4: IGF-1, fasting glucose
- Week 12: Full panel
When to dose-reduce or stop
- IGF-1 > age-adjusted ULN (typically >250 ng/mL in adults 30-50) → reduce to 1 mg daily
- HbA1c rising >0.3 points → investigate glucose management
- Persistent peripheral edema or carpal tunnel symptoms → reduce dose or discontinue
- Any new palpable mass, unexplained weight loss, or red-flag symptom → cancer workup before continuing
Goal: combine tesamorelin with a ghrelin-receptor agonist for greater GH pulse amplitude — the mechanistic argument for the "tesa + ipa" stack.
Tesamorelin + Ipamorelin — 12-24 weeks
- Tesamorelin: 2 mg SC once daily, pre-bed, fasted
- Ipamorelin: 200 mcg SC at the same injection (drawn into the same syringe)
- Rationale: Tesamorelin activates the GHRHR pathway (Gs / cAMP / PKA); ipamorelin activates GHS-R1a (Gq/11 / PLC / IP3 / Ca2+). The two pathways converge on pituitary somatotrophs through distinct second messengers and produce a 3-5x larger GH pulse than either agent alone (Bowers et al., 1991). This is the most potent GHS configuration outside of direct recombinant GH
Why tesamorelin + ipamorelin over MOD-GRF 1-29 + ipamorelin
- Tesamorelin has stronger and more durable visceral-fat effects (~18% VAT reduction at 26 weeks, clinically proven)
- Longer GHRHR receptor occupancy (30-50 min vs 30 min for MOD-GRF) — slightly amplified GH pulse
- FDA-approved quality / regulatory-grade sourcing available (vs research-grade MOD-GRF)
- Higher cost is the primary trade-off
Timing optimization
- Pre-bed, 2+ hours post-meal — leverages the nocturnal GH burst
- For body-composition-focused protocols, some users add a morning fasted dose (ipamorelin 200 mcg SC, no tesamorelin in AM). Tesamorelin dosing beyond 2 mg/day is not recommended — the dose-response plateaus
Cycling
- 12 weeks on / 4 weeks off is the conservative approach
- 26-week continuous protocol (matching the FDA pivotal trial) is appropriate for established visceral adiposity; extension studies confirm safety to 52 weeks
- Off-cycle IGF-1 should return toward baseline within 4-6 weeks; persistent elevation suggests need for monitoring before restarting
Bloodwork on the stack
- Baseline: IGF-1, fasting glucose, HbA1c, insulin, comprehensive metabolic panel, lipid panel, PSA (men >40), thyroid, DEXA or CT for VAT baseline
- Week 4-6: IGF-1, fasting glucose, insulin
- Week 12: Full panel + repeat body composition measurement
- End of cycle: Full panel
Goal: maximize visceral-fat reduction and body composition change in the context of intensive metabolic therapy. For experienced users with full lab monitoring.
Tesamorelin + Ipamorelin + MOD-GRF 1-29 pulsed — 16-24 weeks
For users pursuing maximal GH pulse density while keeping within the physiologic envelope:
- Tesamorelin 2 mg SC pre-bed + ipamorelin 200 mcg in the same injection (primary nocturnal pulse)
- MOD-GRF 1-29 100 mcg + ipamorelin 200 mcg SC in the morning fasted window (secondary morning pulse)
- Total: two discrete GH pulses per day, one driven by tesamorelin's longer receptor occupancy, one driven by the shorter MOD-GRF 1-29 pharmacokinetics
Combined with Semaglutide or Tirzepatide for recomposition
The GHS stack preserves lean body mass during the caloric deficit induced by GLP-1 therapy — one of the most effective body recomposition strategies available in 2026:
- GLP-1 therapy → controlled weight loss, mostly fat mass but 10-20% is typically lean mass
- Tesamorelin + ipamorelin → GH/IGF-1-mediated lean mass preservation + preferential visceral fat targeting
- Net: greater lean mass retention and stronger visceral-fat reduction than GLP-1 alone
For NAFLD / metabolic dysfunction-associated steatohepatitis (MASH)
Off-label use of tesamorelin 2 mg/day for hepatic fat reduction is supported by the Stanley 2014 trial. For users with documented NAFLD (imaging-confirmed hepatic fat fraction >5%):
- Tesamorelin 2 mg daily for 6-12 months
- Consider stacking with NAD+ / NMN for hepatic mitochondrial support
- Monitor ALT, AST, GGT monthly; MRI-PDFF or FibroScan at baseline and 6 months
Cycling considerations
- 16-26 weeks on / 4-6 weeks off is the upper-end protocol
- Long-term (>12 months continuous) requires quarterly bloodwork and annual reassessment
- Tachyphylaxis is not well-characterized for tesamorelin but is less concerning than for CJC-1295-DAC due to pulsatile dosing
Contraindications specific to advanced dosing
- Any active malignancy (absolute)
- History of pituitary or hypothalamic injury / surgery
- Active diabetic retinopathy
- Severe insulin resistance or uncontrolled T2DM
- History of acromegaly
- Known hypersensitivity to tesamorelin or mannitol (an excipient in the commercial formulation)
Weight-Based Dosing
Commonly Stacked With
Tier 1 — The canonical GHS stack: Ipamorelin at 200 mcg per tesamorelin injection. This is the standard biohacking configuration and produces 3-5x larger GH pulses than tesamorelin alone via GHRH × ghrelin pathway synergy. Same injection, same syringe.
Tier 2 — Metabolic / body recomposition stacks:
- Semaglutide or Tirzepatide — the recomposition stack. GLP-1 therapy produces caloric deficit and fat loss; tesamorelin + ipamorelin preserves lean mass and preferentially targets visceral fat. Time the GH secretagogue pulse opposite to the GLP-1 peak (tesamorelin pre-bed, GLP-1 morning or weekly)
- BPC-157 + TB-500 — GH/IGF-1 elevation amplifies the collagen synthesis that BPC-157 and TB-500 enable. Useful for tendon/ligament rehabilitation concurrent with body composition work
- NAD+ / NMN — mitochondrial support during elevated protein synthesis and fat oxidation; particularly useful in NAFLD off-label protocols
- Testosterone (TRT) or Enclomiphene — HPG and GH axes are independent; combined optimization is standard in integrative hormone clinics
Tier 3 — Advanced / specific-use stacks:
- MOD-GRF 1-29 / CJC-1295 — for tri-daily GH pulse protocols, tesamorelin pre-bed + MOD-GRF 1-29 in the morning fasted window (both with ipamorelin). Exploits the different pharmacokinetics of the two GHRH analogs
- Epithalon — longevity-framed stack; combines GH axis amplification with pineal and telomere support
- GHK-Cu — skin and connective tissue regeneration synergy with GH-axis anabolism
DO NOT stack:
- CJC-1295 with DAC — redundant at GHRHR and directly contradicts the pulsatile pharmacodynamics that makes tesamorelin developable. CJC-1295-DAC's ~8-day half-life produces continuous GH elevation; adding tesamorelin is mechanistically confused. Use one or the other
- Exogenous recombinant GH (Somatropin) — defeats the purpose; somatropin directly replaces GH, bypassing the pituitary pulse mechanism tesamorelin enables. Use one or the other
- Other GHRH analogs simultaneously — tesamorelin + sermorelin or tesamorelin + MOD-GRF 1-29 at the same injection is redundant (same receptor). The "tri-daily with different GHRH analogs at different times" protocol is the correct way to stack multiple GHRH analogs — not same-injection
Practical notes
- Tesamorelin + ipamorelin can be drawn into the same syringe and injected together — chemically compatible
- Separate ipamorelin + MOD-GRF 1-29 from tesamorelin when used in tri-daily protocols (different injections, different times)
- For multi-peptide stacks including BPC-157 / TB-500, use separate injection sites — BPC-157 benefits from local delivery near target tissue
Side Effects & Safety
Contraindications
**Absolute contraindications (per FDA label)** - **Disruption of the hypothalamic-pituitary axis** — pituitary tumor or removal, hypopituitarism, hypothalamic injury. Tesamorelin requires an intact pituitary to work and can potentially accelerate residual tumor growth - **Active malignancy** — GH/IGF-1 axis may accelerate tumor growth. Absolute contraindication during active cancer treatment or within 5 years of complete remission - **Pregnancy** — category X; do not use - **Active proliferative or severe non-proliferative diabetic retinopathy** — GH elevation can worsen retinopathy - **Known hypersensitivity to tesamorelin or mannitol** (excipient in commercial formulation) **Additional off-label biohacking contraindications** - **Uncontrolled T2DM** — tesamorelin acutely impairs glucose tolerance; should be optimized before starting - **Active diabetic retinopathy** (any grade) — even non-proliferative - **History of acromegaly or pituitary adenoma** — absolute - **Severe heart failure (NYHA III-IV)** — fluid retention can precipitate decompensation - **Acute critical illness** — tesamorelin is not safe during severe acute illness (sepsis, post-surgical critical care); this mirrors recombinant GH warnings **Relative contraindications (consult physician before use)** - **Type 2 diabetes or pre-diabetes** — use with monitoring; expect HbA1c elevation of ~0.1-0.3 points - **Uncontrolled hypertension** — fluid retention can exacerbate blood pressure - **History of carpal tunnel syndrome** — fluid retention can reactivate symptoms - **Hypothyroidism** — thyroid status affects GH axis; optimize thyroid first - **Age >70** — limited efficacy data; safety data from HIV trials does not include most elderly populations **Drug interactions** - **Glucocorticoids (chronic systemic)** — suppress GH axis and blunt tesamorelin efficacy - **Insulin and oral hypoglycemics** — tesamorelin's effect on glucose tolerance may require dose adjustments - **CYP3A4 substrates** — tesamorelin is not a CYP3A4 inhibitor or inducer; minimal interactions - **Exogenous recombinant GH** — do not combine; redundant - **Other GHRH analogs** — do not use simultaneously at the same receptor **Monitoring requirements** - **Baseline:** IGF-1, fasting glucose, HbA1c, complete metabolic panel, thyroid (TSH, free T4), PSA (men >40), CBC, lipid panel - **Week 4-6:** IGF-1 (target: within age-adjusted reference range, typically <250 ng/mL for adults 30-50) - **Every 12 weeks on therapy:** IGF-1, HbA1c, fasting glucose - **Annually:** Full panel + reassess need for continued therapy **Discontinuation criteria** Stop tesamorelin and consult a clinician if you develop: - IGF-1 > age-adjusted upper limit - HbA1c rising >0.4 points within one cycle - Persistent peripheral edema or new carpal tunnel symptoms - Any new palpable mass, changing mole, or unexplained weight loss (cancer workup indicated) - Severe headache, visual changes (rule out pituitary pathology) - Signs of fluid overload or CHF decompensation
Additional Notes
Standard therapeutic dose: 2 mg subcutaneous, once daily, pre-bed, fasted.
This dose is the FDA-approved dose for HIV lipodystrophy and is the dose used across all major clinical trials. Dose escalation above 2 mg/day has been studied (up to 4 mg/day) and does not produce proportional IGF-1 elevation — the dose-response curve flattens — while the side-effect burden rises substantially (more edema, more carpal tunnel risk, more arthralgia).
Fasted state is essential. Elevated insulin suppresses GH release through multiple mechanisms (increased somatostatin tone, reduced somatotroph cAMP sensitivity). Post-meal tesamorelin dosing can cut the GH pulse by 50-70% — the same fasted-state requirement as all GHRH analogs.
Dose conversions (2 mg vial + 2.1 mL sterile saline per FDA label)
- Concentration: ~0.95 mg/mL
- 2 mg dose = 2.1 mL = entire reconstituted vial each day (per label)
- Commercial Egrifta SV: pre-loaded single-use syringes
For compounded / research-use tesamorelin
- Typical: 5 mg vial + 2.5 mL bacteriostatic water = 2 mg/mL
- 2 mg dose = 1 mL = 100 units on a 1 mL insulin syringe
- Alternative: 1 mg vial + 1 mL BAC water = 1 mg/mL, 2 mg dose = 2 mL (impractical; use 5 mg vials)
Timing
- Pre-bed (evening, 2+ hours post-meal) is the FDA-approved timing and the most physiologic — amplifies the largest endogenous GH pulse of the day
- Morning fasted is NOT an alternative timing — the MOD-GRF 1-29 pre-bed dose leverages the nocturnal GH architecture; moving tesamorelin to morning reduces efficacy
- NOT pre-workout — peri-exercise insulin and metabolic shifts blunt response; training's natural GH pulse does not benefit from superimposed tesamorelin
Interactions with nutrition
- Carbohydrates and protein both elevate insulin, blunting GH response — fasted state required
- Caffeine is neutral (may slightly enhance via mild adrenergic effect)
- Alcohol independently suppresses GH secretion — avoid within 4 hours of dosing
Dose adjustments in specific populations
- Renal impairment (eGFR <60): dose reduction typically not required; monitor
- Hepatic impairment: use with caution; hepatic IGF-1 production may be impaired
- Age >65: some clinicians start at 1 mg and titrate; age-related declines in GHRH sensitivity are modest but present
- Active T2DM: 1 mg initial dose with close glucose monitoring; escalate only if glucose control is maintained
See the Reconstitution Tool for any custom vial size / diluent volume calculation.
Where to Buy Tesamorelin
Compare 14 listings across 7 vendors — from $44.99
Frequently Asked Questions
What is the recommended Tesamorelin dosage?
The typical dose range for Tesamorelin is 1,000–2,000 mcg (1–2 mg) daily. It is usually administered Once daily subcutaneous injection. Always start with the lowest effective dose.
How often should I take Tesamorelin?
Once daily subcutaneous injection
Does Tesamorelin need to be cycled?
Yes, typical cycle length is 12–26 weeks in clinical trials; ongoing use common.
What are Tesamorelin side effects?
Tesamorelin has a **well-characterized side-effect profile** from the FDA approval program, which is a significant advantage over non-approved GHRH analogs. **Common (>10% in Phase 3 trials)** - **Injection site reactions** — erythema, pruritus, pain at site; most frequent adverse event (~22% of patients); usually mild and resolves with site rotation - **Arthralgia** (joint aches) — IGF-1-mediated connective tissue effect; typically appears 4-8 weeks into dosing and stabilizes - **Pain in extremities** — related to fluid shifts and peripheral tissue expansion - **Myalgia** — mild muscle aches, also from IGF-1-mediated connective tissue changes - **Peripheral edema** — dose-dependent GH-mediated fluid retention; mild and usually resolves within weeks **Uncommon (1-10%)** - **Carpal tunnel symptoms** — fluid-shift-mediated peripheral compression; should prompt dose reduction or discontinuation - **Paresthesias (hand tingling)** — early sign of fluid retention - **Insulin resistance / elevated fasting glucose** — all GH-elevating therapies impair glucose tolerance; in Phase 3 trials, HbA1c rose by ~0.1% absolute on tesamorelin vs placebo — clinically small but monitor - **Rash / urticaria** — hypersensitivity-spectrum reactions **Rare but important** - **Hyperglycemia / new-onset diabetes** — rare in the Phase 3 trials; however, patients with pre-existing diabetes or pre-diabetes require close monitoring - **Fluid retention with CHF** — contraindicated in patients with acute critical illness, heart failure, or severe edema - **IGF-1 elevation above age-adjusted upper limit** — ~5% of patients in Phase 3 had IGF-1 > ULN; requires dose reduction **Black box / boxed warnings** — Tesamorelin has NO FDA black box warning. This is notable: recombinant GH (Somatropin) carries boxed warnings for critical-illness mortality; tesamorelin does not. **Contraindications per FDA label** - **Disruption of the hypothalamic-pituitary axis** (pituitary tumor removal, hypopituitarism, hypothalamic injury) - **Active malignancy** — absolute; GH/IGF-1 axis may accelerate tumor growth - **Pregnancy** — contraindicated - **Pediatrics** — not studied **What tesamorelin DOES NOT do** - Does NOT elevate prolactin or cortisol (unlike GHRP-2/6 / hexarelin) - Does NOT cause the continuous GH elevation of CJC-1295-DAC - Does NOT cause the acromegalic-body-composition changes of chronic recombinant GH (because the pulse pattern preserves physiologic regulation) - Does NOT cause injection-site lipodystrophy seen with some older peptide injections **Monitoring requirements** Per FDA label and standard clinical practice: - **Baseline:** IGF-1, fasting glucose, HbA1c, comprehensive metabolic panel, thyroid (TSH, free T4) - **Weeks 4-8:** IGF-1 — target within age-adjusted reference range; dose-reduce or discontinue if ULN exceeded - **Quarterly (on long-term therapy):** HbA1c, fasting glucose, liver function, IGF-1 - **Annually:** Reassess need for continued therapy (it is suppressive, not curative) **Long-term safety framing** The Phase 3 + extension data covers ~2 years; beyond that, safety is extrapolated from the broader GH/IGF-1 literature. Active surveillance for malignancy (general cancer screening appropriate for age and sex), periodic IGF-1 monitoring, and glucose/HbA1c surveillance are the standard clinical practices for adults on tesamorelin beyond 2 years.
Where can I buy Tesamorelin?
Compare 14 listings from 7 vendors on our price comparison page — starting from $44.99.
Free 2026 Peptide Cheat Sheet — 50 pages, PDF
Dosing, reconstitution, stacks, half-lives, and vendor trust tiers. The reference we wish we had on day one.